| Compound | Dermorphin |
|---|---|
| Category | Amphibian opioid peptide |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Dermorphin is catalogued here as a amphibian opioid peptide and graded at the "Minimal evidence" evidence tier. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A potent opioid peptide discovered in frog skin. It has no legitimate medical use, and its detection in racehorses led to major doping scandals.
Mechanism of Action
Dermorphin is an extremely potent mu-opioid receptor agonist — far more potent than morphoid peptides — which is precisely why it has attracted both abuse and analytical scrutiny.
Research and Evidence
No human therapeutic trials; veterinary forensic detection literature documents its misuse.
Safety and Side Effects
Opioid-class potency with no human safety characterization; respiratory-depression risk is inherent to the mechanism, and legal exposure is severe.
Frequently Asked Questions
What is the evidence tier of Dermorphin?
Dermorphin is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is Dermorphin an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Dermorphin?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for dermorphin studies (none registered). [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.